Asia · Financial press · SCMP Business

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

Published by SCMP Business · Hong Kong 2 h ago

Detailed summary

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug…

Read the full article on SCMP Business Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.scmp.com)

Also worth reading

The Economic Times

India equity surge brightens outlook for exchanges, brokerages

Caixin Global

Caixin Summit: U.S.-China Stability Is Tactical, Not Strategic, Rudd Says

Nikkei Asia